Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferriprox for Iron Overload in Sickle Cell Disease
NCT02041299Phase 4Terminated
- Sponsor
- ApoPharma Inc.
- Start
- Apr 2014
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial of deferiprone in iron overload (2 arms), sponsored by ApoPharma Inc. Primary endpoint: Liver Iron Concentration at 52 weeks. Started Apr 2014; status: terminated.
02
Drugs
deferiprone
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT02041299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041299.